CTOs on the Move

Cadila Pharmaceuticals - CPL

www.cplinc.net

 
Cadila Pharmaceuticals - CPL, Inc. is a Chesterfield, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.cplinc.net
  • 16020 Swingley Ridge Rd Ste 145
    Chesterfield, MO USA 63017
  • Phone: 636.728.1980

Executives

Name Title Contact Details

Similar Companies

St. Joseph Children's Home

We providing a continuum of care through our three programs: Foster Care and Adoption Program, Residential Treatment Program, and Child Development Center.

Enalare Therapeutics

Enalare Therapeutics Inc. is a privately owned clinical-stage biopharmaceutical company dedicated to developing novel therapies for patients suffering from acute respiratory conditions.

Innocrin Pharmaceuticals

Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.

Articularis Healthcare Group

A physician led and owned organization committed to improving healthcare by supporting independent rheumatology practices across the nation and providing innovative technology to lower healthcare costs for providers and patients

Saluda Medical

Saluda Medical is a global medical device company focused on patient outcomes, science, and engineering to transform the neuromodulation industry with a platform of closed-loop technologies that optimize therapy by reading, recording, and responding to the nerves' response to stimulation` The company's first product, Evoke®, is the only ECAP-controlled closed-loop spinal cord stimulation (SCS) system designed to treat chronic pain, a condition that affects more than 540 million people globally` SCS treats the condition by stimulating the spinal cord and altering the transmission of pain signals to the brain` Saluda's proprietary Evoke System is the only closed-loop SCS system designed to maintain individualized, consistent therapy by precisely controlling spinal cord activation through real-time customization of waveforms on every evoked compound action potential (ECAP) at the same rate as the stimulation frequency (At stimulation frequency of 40 Hz, 40 adjustments are made each second, 3`5 million adjustments per day, and 1`2 billion adjustments per year)`